Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Gestraud

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Nature|April 26, 2023
A druggable copper-signalling pathway that drives inflammationStéphanie Solier, Sebastian Müller, Tatiana Cañeque, et al.
Nature|September 7, 2022
Genomics to select treatment for patients with metastatic breast cancerFabrice Andre, Thomas Filleron, Maud Kamal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2023
Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical ModelsElizabeth R Tucker, Irene Jiménez, Lindi Chen, et al.
Leukemia|March 31, 2022
RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemiaJustine Decroocq, Rudy Birsen, Camille Montersino, et al.
NPJ Precision Oncology|January 10, 2026
Ex vivo drug sensitivity profiling to complement molecular profiling in pediatric precision oncologyMarlinde C Schoonbeek, Pierre Gestraud, Lindy Vernooij, et al.
Ebiomedicine|July 11, 2020
Corrigendum to 'clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome'Suzy Scholl, Marina Popovic, Anne de la Rochefordiere, et al.
Ebiomedicine|April 7, 2019
Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcomeSuzy Scholl, Marina Popovic, Anne de la Rochefordiere, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Nature|April 26, 2023
A druggable copper-signalling pathway that drives inflammationStéphanie Solier, Sebastian Müller, Tatiana Cañeque, et al.
Nature|September 7, 2022
Genomics to select treatment for patients with metastatic breast cancerFabrice Andre, Thomas Filleron, Maud Kamal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2023
Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical ModelsElizabeth R Tucker, Irene Jiménez, Lindi Chen, et al.
Leukemia|March 31, 2022
RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemiaJustine Decroocq, Rudy Birsen, Camille Montersino, et al.
NPJ Precision Oncology|January 10, 2026
Ex vivo drug sensitivity profiling to complement molecular profiling in pediatric precision oncologyMarlinde C Schoonbeek, Pierre Gestraud, Lindy Vernooij, et al.
Ebiomedicine|July 11, 2020
Corrigendum to 'clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome'Suzy Scholl, Marina Popovic, Anne de la Rochefordiere, et al.
Ebiomedicine|April 7, 2019
Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcomeSuzy Scholl, Marina Popovic, Anne de la Rochefordiere, et al.
Pageof 4